Related Experiment Videos
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).
Robert T Chen1, Baevin Carbery2, Lisa Mac1
1DHAP, NCHHSTP, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA.
Vaccine
|October 12, 2014
Summary
Recombinant viral vectors are promising for vaccines against pathogens like Ebola and tuberculosis. A safety working group was formed to address potential issues and improve public trust in these novel vaccine technologies.
Area of Science:
- Vaccinology
- Virology
- Immunology
Background:
- Recombinant viral vectors enable effective in vivo heterologous antigen expression.
- These vectors are promising platforms for novel vaccines targeting diverse human pathogens, including Ebola and tuberculosis.
- Numerous candidate viral vector vaccines are progressing into human clinical trials.
Purpose of the Study:
- To establish the Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).
- To enhance the anticipation and assessment of safety issues related to viral vector vaccines.
- To facilitate greater public acceptance of licensed viral vector vaccines.
Main Methods:
- Formation of a dedicated safety working group.
- Development of frameworks for safety data assessment and interpretation.
- Collaboration among experts in viral vector vaccine safety.
Main Results:
- Established the Viral Vector Vaccines Safety Working Group (V3SWG).
- Initiated efforts to improve safety issue anticipation.
- Aimed to standardize safety data assessment for viral vector vaccines.
Conclusions:
- Viral vector vaccines represent a significant advancement in vaccinology.
- Proactive safety assessment is crucial for the successful development and public acceptance of viral vector vaccines.
- The V3SWG will play a key role in ensuring the safety and efficacy of future viral vector vaccines.